Neuromodulation – ECT, rTMS, DBS

Synofzik, Matthis; Schläepfer, Thomas E.

doi:10.1007/978-90-481-8721-8_19

Cited by 8 publications

(2 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, adverse effects of antidepressive pharmacological interventions can be severe regarding both their utilization and discontinuation (Henssler et al, 2019). Brain stimulation treatments such as electroconvulsive therapy, repetitive transcranial magnetic stimulation, or deep brain stimulation for passive induction of neuronal plasticity can only be considered for the treatment of specific cases (Synofzik et al, 2010) and may not be used on a widespread basis due to ethical considerations, high technical requirements, and associated expenses.…”

Section: Introductionmentioning

confidence: 99%

Meditation‐based lifestyle modification in mild to moderate depression—A randomized controlled trial

Bringmann

Michalsen

Jeitler

et al. 2022

Depression and Anxiety

View full text Add to dashboard Cite

Objective: Depression is a global key challenge in mental health care. The implementation of effective, low-risk and cost-effective interventions to reduce its disease burden is a necessity. The aim of this study was to investigate the efficacy of the new Meditation-Based Lifestyle Modification (MBLM) program, a "secondgeneration" mindfulness-based intervention, in depressive outpatients. Methods: Eighty-one patients with mild to moderate depression were randomized into three groups: intervention group (MBLM), control group (CONTROL), and treatment as usual group (TAU). The primary outcome was the change of depressive symptoms as administered by the Beck Depression Inventory-II (BDI-II) after 4 and 8 weeks. Secondary outcome variables included the Brief Symptom Checklist-18 and the Perceived Stress Scale-10. A 6-month follow-up was conducted. Results: A greater reduction of depressive symptoms was found in MBLM participants compared to CONTROL (p < .001, η p 2 = 0.11, d = 0.70) and TAU (p η d < .001, = 0. 10, = 0. 67 p 2 ) with a 13.15 points reduction of BDI-II score versus 1.71 points (CONTROL) and 3.34 points (TAU) after 8 weeks. Betweengroup post hoc tests for all secondary outcomes and at follow-up also yielded significant between-group differences with medium to large effect sizes in favor of MBLM. Conclusions: Study results showed beneficial effects of MBLM in depressed outpatients. Further high-quality controlled clinical studies including qualitative research are needed to investigate the specific and unspecific effects of the MBLM program in depression and other medical conditions.

show abstract

Section: Introductionmentioning

confidence: 99%

Meditation‐based lifestyle modification in mild to moderate depression—A randomized controlled trial

Bringmann

Michalsen

Jeitler

et al. 2022

Depression and Anxiety

View full text Add to dashboard Cite

show abstract

“…Therefore, we strongly propose that the instrument to assess motivations and perceptions of risks and benefits, which is proposed by Dunn and colleagues for DBS studies for TRD (Dunn et al 2011), should also be applied in informed consent procedures for neurologic DBS in both research participation and treatment decisions. Such a thorough assessment of patient's perceptions and motivations is of upmost critical importance in any field of DBS, as misconceptions may commonly result not only from desperation, but also from a patient's exposition to public events, videotapes, or media coverage showing dramatic improvements in target symptoms after surgical intervention ("DBS miracles") (Okun and Foote 2004;Racine et al 2007), but give much less emphasis to adverse events, such as haemorrhages, dysarthria, psychosocial maladjustments, or insufficient treatment responses (Synofzik and Schlaepfer 2010).…”

Section: Optimizing Informed Consent In Neurologic Dbsmentioning

confidence: 99%